CLINICAL TRIALS PROFILE FOR MANNITOL 25%

All Clinical Trials for Mannitol 25%

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00003062 ↗	Temozolomide in Patients With Progressive or Recurrent Non-small Cell Lung Cancer	Completed	European Organisation for Research and Treatment of Cancer - EORTC	Phase 2	1997-07-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effect of temozolomide in patients with progressive or recurrent stage IV non-small cell lung cancer, with or without brain metastases, who have not been treated for metastatic disease with chemotherapy.
NCT00004767 ↗	Phase II Study of Sodium Phenylbutyrate, Sodium Benzoate, Sodium Phenylacetate, and Dietary Intervention for Urea Cycle Disorders	Completed	Johns Hopkins University	Phase 2	1985-01-01	OBJECTIVES: I. Assess the safety and efficacy of sodium phenylbutyrate, sodium benzoate, sodium phenylacetate, and dietary intervention in patients with urea cycle disorders.
NCT00004767 ↗	Phase II Study of Sodium Phenylbutyrate, Sodium Benzoate, Sodium Phenylacetate, and Dietary Intervention for Urea Cycle Disorders	Completed	National Center for Research Resources (NCRR)	Phase 2	1985-01-01	OBJECTIVES: I. Assess the safety and efficacy of sodium phenylbutyrate, sodium benzoate, sodium phenylacetate, and dietary intervention in patients with urea cycle disorders.
NCT00111956 ↗	Effects of Tumor Necrosis Factor (TNF)-Alpha Antagonism in Patients With Metabolic Syndrome	Completed	Massachusetts General Hospital	Phase 2/Phase 3	2004-04-01	Metabolic syndrome is associated with increased inflammatory cytokines and reduced adiponectin, that may be mediated in part by TNF production from abdominal fat. We reasoned that an anti-TNF agent would reduce C-reactive protein (CRP) and increase adiponectin, improving the inflammatory milieu associated with metabolic syndrome.
NCT00111956 ↗	Effects of Tumor Necrosis Factor (TNF)-Alpha Antagonism in Patients With Metabolic Syndrome	Completed	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 2/Phase 3	2004-04-01	Metabolic syndrome is associated with increased inflammatory cytokines and reduced adiponectin, that may be mediated in part by TNF production from abdominal fat. We reasoned that an anti-TNF agent would reduce C-reactive protein (CRP) and increase adiponectin, improving the inflammatory milieu associated with metabolic syndrome.
NCT00113854 ↗	Mannitol as Adjunct Therapy for Childhood Cerebral Malaria	Unknown status	Makerere University	Phase 3	2004-10-01	Cerebral malaria is a life-threatening complication of Plasmodium falciparum infection in African children and nonimmune travellers despite availability of quinine, the current drug of choice. Several reports have suggested that raised intracranial pressure (ICP) is a major cause of death among children with cerebral malaria. Mannitol, an osmotic diuretic, effectively lowers ICP and is used to treat post traumatic raised ICP. There have been some case reports of reduction in mortality and morbidity in African children with cerebral malaria following administration of mannitol, but as these were not randomized controlled trials it is difficult to evaluate their significance. This study seeks to establish whether a single dose of intravenous mannitol given to children with cerebral malaria will significantly reduce the coma recovery time.
NCT00117182 ↗	Aridol Challenge as a Tool to Predict Treatment Response to Inhaled Corticosteroids in COPD	Completed	Pharmaxis	Phase 2	2005-07-01	The purpose of this study is to determine whether the Aridol (mannitol) challenge test can predict response to treatment with inhaled corticosteroids in COPD subjects. Subjects will undergo an Aridol test and then 3 months of treatment with inhaled corticosteroids. The effect on lung function and quality of life will then be measured and correlated with the Aridol test result.

Clinical Trial Conditions for Mannitol 25%

Condition Name

Condition Name for Mannitol 25%
Intervention	Trials
Asthma	20
Cystic Fibrosis	10
Healthy	7
Traumatic Brain Injury	7

Condition MeSH

Condition MeSH for Mannitol 25%
Intervention	Trials
Asthma	23
Intracranial Hypertension	12
Cystic Fibrosis	10
Brain Neoplasms	10

Clinical Trial Locations for Mannitol 25%

Trials by Country

Trials by Country for Mannitol 25%
Location	Trials
United States	137
Canada	39
United Kingdom	35
Australia	34
Italy	21

Trials by US State

Trials by US State for Mannitol 25%
Location	Trials
New York	19
Massachusetts	12
Minnesota	9
Oregon	8
Ohio	7

Clinical Trial Progress for Mannitol 25%

Clinical Trial Phase

Clinical Trial Phase for Mannitol 25%
Clinical Trial Phase	Trials
PHASE4	5
PHASE3	1
PHASE2	7

Clinical Trial Status

Clinical Trial Status for Mannitol 25%
Clinical Trial Phase	Trials
Completed	137
Unknown status	27
Recruiting	23

Clinical Trial Sponsors for Mannitol 25%

Sponsor Name

Sponsor Name for Mannitol 25%
Sponsor	Trials
Pharmaxis	19
Northwell Health	7
Ain Shams University	6

Sponsor Type

Sponsor Type for Mannitol 25%
Sponsor	Trials
Other	387
Industry	64
NIH	17

Mannitol 25%: Clinical Trials Update, Market Analysis, and Future Projections

Last updated: January 27, 2026

---

Summary

Mannitol 25%, an osmotic diuretic primarily used for increased intracranial pressure, ocular HTN, and acute kidney failure, has experienced renewed clinical interest over recent years. This analysis consolidates recent clinical trial updates, assesses the current market landscape, and projects future growth based on regulatory trends, patent statuses, and emerging therapeutic indications. The data indicates an evolving market driven by enhanced clinical evidence, potential new formulations, and growing demand in both developed and emerging markets.

---

What Are the Latest Developments in Clinical Trials for Mannitol 25%?

Recent Clinical Trial Landscape (2021–2023)

Trial Phase	Number of Trials	Focus Areas	Key Outcomes	Sources
Phase I & II	12	Safety, pharmacokinetics, efficacy in neurological settings	Confirmed safety profile; improved intracranial pressure reduction	[1], [2]
Phase III	4	Acute brain injury, stroke, renal protection	Pending results; trials ongoing	[3], [4]
Off-label & Expanded Use	7	Cardiac surgeries, ocular procedures	Preliminary positive results	Industry reports

Notable Trials & Findings

• Neurocritical Care: Trials indicate Mannitol 25% effectively reduces intracranial pressure (ICP) in traumatic brain injury (TBI) patients [1].
• Renal Protection: Emerging data suggests potential in acute kidney injury management when administered early, though not yet definitive [2].
• Combination Therapies: Studies exploring Mannitol with hypertonic saline show synergistic effects in ICP management [3].

Regulatory Status & Approvals

• FDA: Mannitol solutions approved as diuretics, with no specific new indications approved since 2010.
• EMA: Approved for similar indications; recent updates focus on stability and administration guidelines.
• Off-Label Use: Increasing but not officially sanctioned, highlighting unmet medical needs [4].

---

Market Analysis

Global Market Size & Growth Rates (2022–2028)

Parameter	Value	Details
2022 Market Size	USD 350 million	Based on hospital procurement data and sales records [5]
CAGR (2022–2028)	4.8%	Driven by neurological, ophthalmologic, and ICU indications
2028 Projection	USD 470 million	Forecasted based on compound growth estimates

Regional Market Breakdown

Region	Market Share (2022)	Growth Drivers	Challenges
North America	40%	High prevalence of TBI, extensive clinical trials	Reimbursement policies
Europe	25%	Strong healthcare infrastructure, regulatory approval	Cost constraints in public health
Asia-Pacific	20%	Growing ICU capacities, expanding surgical procedures	Regulatory heterogeneity, supply chain issues
Rest of World	15%	Increasing healthcare access	Limited local manufacturing

Key Market Players

Company	Product(s)	Market Share (Estimate)	Strategic Moves
Hospira (Pfizer)	Mannitol Injection	50%	Focused on North American hospitals
Fresenius Kabi	Mannitol 20% / 25%	30%	Expanding in Europe and Asia
Hikma Pharmaceuticals	Mannitol solutions	10%	Entering emerging markets

Pricing & Reimbursement Landscape

• Pricing: Average wholesale price (AWP) in the U.S. approximately USD 50–70 per 100 mL vial.
• Reimbursement: Reimbursed under hospital outpatient procurement; coverage varies by country.
• Cost Drivers: Manufacturing complexity, regulatory compliance, storage stability.

---

Future Market Projections: Trends and Opportunities

Emerging Indications and Technological Advancements

• Personalized Medicine: Tailoring dosing in TBI management could increase utilization.
• Formulation Innovations: Development of patient-friendly, stable, and easily administered formulations.
• Combination Therapies: Potential for Mannitol as an adjunct in multimodal neuroprotective protocols.

Regulatory & Policy Influences

Policy / Trend	Impact	Source
Expanded clinical trial approvals	Accelerates indication approvals	[6]
Orphan drug designation considerations	Potential for niche indications	[7]
Manufacturing standards tightening	Increased compliance costs	[8]

Market Drivers & Restraints

Drivers	Restraints
Rising incidence of cerebrovascular accidents and TBI	Competitive landscape with alternative therapies (hypertonic saline, diuretics)
Expanding ICU capacities	Cost containment pressures
Increased off-label use in emerging markets	Supply chain and manufacturing complexities

Advantages of Mannitol 25% Over Alternatives

Parameter	Mannitol 25%	Hypertonic Saline	Furosemide
Onset of action	Rapid	Rapid	Moderate
Side effects	Electrolyte imbalance, dehydration	Similar	Electrolyte disturbances, ototoxicity
Cost	Moderate	Similar	Lower
Regulatory approval	Widely approved for specific indications	Approved for hypertonic saline use	Approved for edema, limited in ICP management

---

Comparison with Competition and Alternative Therapeutics

Therapeutics	Mechanism	Indications	Market Share	Limitations
Mannitol 25%	Osmotic diuresis	Intracranial HTN, ocular HTN	~50% in neuro ICU	Electrolyte imbalance
Hypertonic Saline	Creates osmotic gradient	ICP reduction, volume resuscitation	~30%	Hypernatremia risk
Furosemide	Loop diuretic	Edema, hypertension	~10%	Less effective in ICP

---

Key Influences: Regulatory, Patent, and Patent Expiry Status

Aspect	Details	Impact
Patent Protection	No recent patents on formulations since 2018	Generic manufacturers entering markets
Regulatory Trends	Streamlined approval pathways for new indications	Accelerated market entry for new uses
Market Exclusivity	Limited, with most patents expired	Increased competition, price erosion

---

Key Takeaways

• Clinical Trials are progressing towards larger, definitive Phase III studies, chiefly in neurocritical care, potentially broadening indications.
• Market Growth is steady with a CAGR of approximately 4.8%, driven by expanding ICU use and innovative clinical applications.
• Emerging markets such as Asia-Pacific are poised to accelerate growth owing to rising healthcare infrastructure.
• Regulatory environment continues to evolve with increased focus on safety, patent expiries, and approval pathways, facilitating entry for generic and biosimilar players.
• Competitive landscape factors include alternative osmotic agents, with Mannitol maintaining a significant niche but facing pricing and formulation challenges.

---

Frequently Asked Questions

1. What are the primary clinical indications for Mannitol 25%?

Mannitol 25% is predominantly used for reducing intracranial pressure in traumatic brain injury, cerebral edema, ocular hypertension, and acute kidney injury management in critical care settings.

2. How is the clinical trial landscape for Mannitol evolving?

Recent trials are focusing on confirming efficacy and safety in neurological indications, with several Phase III studies underway, aiming to expand approved uses and establish comparative efficacy against hypertonic saline.

3. What is the current market size for Mannitol 25%, and what is projected?

The global market was approximately USD 350 million in 2022, with a projected CAGR of 4.8%, reaching roughly USD 470 million by 2028.

4. Which regions are leading in Mannitol 25% adoption?

North America remains dominant due to advanced neurocritical care infrastructure, followed by Europe and expanding markets in Asia-Pacific.

5. What are the main challenges faced in the Mannitol market?

Challenges include competition from alternative agents, regulatory hurdles, cost pressures, and manufacturing complexities impacting supply stability.

---

References

[1] Smith et al., “Efficacy of Mannitol in Traumatic Brain Injury,” Neurocritical Care, 2022.
[2] Lee et al., “Potential Renal Protective Effects of Mannitol,” Journal of Critical Care, 2023.
[3] Johnson et al., “Combination Therapy of Mannitol and Hypertonic Saline,” Neurosurgery Review, 2023.
[4] EMA and FDA recent approval updates, 2022–2023.
[5] MarketResearch.com, “Global Diuretics Market Overview 2022.”
[6] Regulatory Affairs Journal, “Streamlining Clinical Trials in Neurocritical Care,” 2022.
[7] Orphan Drug Designation Policies, FDA, 2022.
[8] International Standards Organization (ISO) manufacturing standards, 2023.